

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of treating a pathological condition of the uterus in a female individual, the method comprising:

administering to a female individual, having a pathological condition of the uterus selected from the group consisting of uterine carcinoma, endometriosis, and fibroids ~~associated with abnormal growth of cells of the myometrium or endometrium~~, an F prostanoid (FP) receptor antagonist under conditions effective to treat the pathological condition of the uterus.

2. (Cancelled)

3. (Currently Amended) A method according to Claim 1 wherein the pathological condition of the uterus is uterine carcinoma ~~or an endometrial or myometrial pathological condition~~.

4. (Currently Amended) A method according to Claim [[3]] 1 wherein the ~~endometrial~~ pathological condition is endometriosis.

5. (Currently Amended) A method according to Claim [[3]] 1 wherein the ~~myometrial~~ pathological condition is fibroids.

6-8.(Cancelled)

9. (Previously Presented) A method according to Claim 1 wherein the FP receptor antagonist is any one or more of PGF_{2α} dimethyl amide; PGF_{2α}, dimethyl amine; AL-8810 ((5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanoic acid); AL-3138 (11-deoxy-16-fluoro PGF_{2α}); phloretin; glibenclamide; ridogrel; PHG113, PCP-1 (rvkfksqhrqgrshhlem); PCP-2 (rkavlknyklasqccgvhvislhiwelssiknslkvaaisespvaeksast); PCP-3 (clseeakearrindeierqlrrdkrdarre-NH₂); PCP-4 (kdtlqlnlkeynlv-NH₂); PCP-8 (ilghrdyk); PCP-10 (wedrfyll); PCP-13 (ILGHRDYK); PCP-14 (YQDRFYLL); (ILAHRDYK); PCP-13.7 (ILAHRDYK); PCP-13.8 (ILaHRDYK); PCP-13.11 (ILGFRDYK); PCP-13.13 (ILGHKDYK); PCP-13.14 (ILGHRNYK); PCP-13.18 (ILGHQDYK); PCP-13.20

(ILGHRDY-amide) ; PCP-13.21 (ILGHRDYK-amide); PCP-13.22 (ILGWRDYK); PCP-13.24 (ILGXRDYK); and PCP-15 (SNVLCSIF).

10–11. (Cancelled)

12. (Previously Presented) A method according to Claim 1 further comprising administering to the individual an inhibitor of PGES and/or an antagonist of the E prostanoid receptor 2 (EP2 receptor) or E prostanoid receptor 4 (EP4 receptor).

13. (Previously Presented) A method according to Claim 12 wherein the antagonist of the EP2 or EP4 receptor is one or more of AH6809, an omega-substituted prostaglandin E derivative, AH23848B, AH22921X, a peptide selected from the group consisting of those having the amino acid sequence IFTSYLECL, IFASYECL, IFTSAECL, IFTSYEAL, ILASYECL, IFTSTDCL, XTSYEAL (where X is 4-biphenylalanine), and XTSYEAL (where X is homophenylalanine), a 5-thia-prostaglandin E derivative, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one potassium salt, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-methyl-3-furoyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(3-methyl-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one, 5-butyl-2,4-dihydro-4-[[2'-[N-(2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one, and 5-butyl-2,4-dihydro-4-[[2'-[N-[2-(methypyrrole)carbonyl]sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl}-1,2,4-triazol-3-one.

14–32. (Cancelled)